Sugi Predict

Sugi Predict / Compounds / SCHEMBL1765256

SCHEMBL1765256

SCHEMBL1765256

COc1ccc(Cl)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ TUBB1 Q9H4B7 3/20 0.48
▸ KMT2A Q03164 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ SLC6A2 P23975 2/20 0.46
▸ SLC6A4 P31645 2/20 0.46
▸ KCNH2 Q12809 1/20 0.46
▸ SLC6A3 Q01959 1/20 0.46
▸ KDM1A O60341 2/20 0.46
▸ TRPV4 Q9HBA0 1/20 0.46
▸ PPARG P37231 2/20 0.45
▸ PPARA Q07869 2/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ HTR3E A5X5Y0 1/20 0.43
▸ HTR3B O95264 1/20 0.43
▸ HTR3A P46098 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1023561 0.98 LMNA (0.48) LMNAMAPK1HTTRAB9ATUBB1
SCHEMBL15211455 0.84 TRPV4 (0.52) LMNAHTTKMT2AGAATRPV4
SCHEMBL13906291 0.84 CYP17A1 (0.55) LMNAMAPK1HTTRAB9AKMT2A
SCHEMBL22737966 0.79 HSP90AA1 (0.46) LMNAKMT2AGAATRPV4ALDH1A1
SCHEMBL20209464 0.79 HSP90AA1 (0.43) LMNAKMT2AGAATRPV4MEN1
SCHEMBL24252062 0.78 SLC6A4 (0.44) LMNAKMT2AGAASLC6A2SLC6A4
SCHEMBL29636402 0.78 TRPV4 (0.55) LMNAMAPK1KMT2AGAASLC6A2
SCHEMBL2127233 0.78 TRPV4 (0.55) LMNAMAPK1KMT2AGAASLC6A2
SCHEMBL5769814 0.78 S1PR4 (0.45) LMNAMAPK1HTTKMT2ASLC6A2
SCHEMBL20209151 0.78 LMNA (0.40) LMNAMAPK1HTTRAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466803-B2 BCKDK inhibitors and/or degraders PFIZER INC. (US) 2025-11-11 — — US disclosed
CN-118693282-B Secondary battery and preparation method and application thereof 蜂巢能源科技股份有限公司 2024-12-03 — — CN disclosed
CN-118693282-A Secondary battery and preparation method and application thereof 蜂巢能源科技股份有限公司 2024-09-24 — — CN disclosed
CN-118451066-A 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure 辉瑞大药厂 2024-08-06 — — CN disclosed
WO-2023100061-A1 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE PFIZER INC. (US) 2023-06-08 — — WO disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 — — US disclosed
US-20230159512-A1 COMPOUNDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. 2023-05-25 — — US disclosed
US-11274101-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-15 — — US disclosed
US-11242348-B2 — — 2022-02-08 — — US disclosed
EP-3889156-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2021-10-06 — — EP disclosed
EP-0851524-A1 Non-aqueous electrolyte secondary cell SONY CORPORATION (JP) 1998-07-01 — — EP disclosed
EP-0734363-A1 FLUORINATION PROCESS BNFL FLUOROCHEMICALS LTD. (GB) 1996-10-02 — — EP disclosed
WO-1995016649-A1 FLUORINATION PROCESS BNFL FLUOROCHEMICALS LTD. (GB) 1995-06-22 — — WO disclosed
CN-1027069-C Process for producing oxazolidinedione derivative SAGAMI CHEM RES (JP) 1994-12-21 — — CN disclosed
CN-1059718-A The weedicide that contains the  oxazolidinedione derivatives SAGAMI CHEM RES (JP) 1992-03-25 — — CN disclosed
CN-87105777-A Heterogeneous ring compound — 1988-04-06 — — CN disclosed
CN-86108416-A Oxazolidinedione derivative, process for producing the same, and herbicide containing the same — 1987-07-29 — — CN disclosed
EP-0227356-A2 The use of depogen in the treatment of restricted blood circulation CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) 1987-07-01 — — EP disclosed
EP-0225175-A2 Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof FISONS plc (GB) 1987-06-10 — — EP disclosed
CN-85108193-A Contain weedicide of aryl triazolineone and preparation method thereof — 1986-12-17 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466803-B2 BCKDK inhibitors and/or degraders BCKDK, KHK, PDK4 LMNA 2031/4885MAPK1 733/4885HTT 2660/4885
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS BCKDK, KHK, PDK4 LMNA 2031/4885MAPK1 733/4885HTT 2660/4885
US-11274101-B2 Heterocyclic compound MAG, HTT, ACHE LMNA 863/4885MAPK1 392/4885HTT 2/4885
US-20230159512-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR LMNA 2442/4885MAPK1 814/4885HTT 778/4885
US-11242348-B2 — MAG, ACHE, GAP43 LMNA 1083/4885MAPK1 494/4885HTT 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.